search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Immune Response Enzyme Immunoassay (EIA) Vaccine Response


The immune response of an individual can vary depending on the nature of the antigen initiating the response. Failure to produce the appropriate specific antibody response or the production of functionally inactive antibodies may result in recurrent and/ or persistent infections. The immune system is able to recognise protein antigens adequately from the first year of life and this is the basis of vaccination policies worldwide. Polysaccharide antigens are more difficult for the immune system to recognise and young children are not able to react to them at all. The ability to respond to polysaccharide antigens starts to mature from the age of 2-3 years until adulthood.


When the immune system loses its functional ability to produce specific antibodies the ability to respond to polysaccharide antigens is the first to diminish while the specific antibody response to protein antigens remains intact for longer. These specific antibody responses are often lost before hypogammaglobulinaemia becomes apparent.


Vaccines can be used to aid in the diagnosis of immunodeficiency. A serum sample is taken from the patient just before vaccination and another is taken 3-4 weeks after vaccination. The samples are tested to measure the specific antibody response to the vaccine(s) administered. Several responses may be tested and it is important to include both protein (e.g. Tetanus or Diphtheria) and pure polysaccharide (i.e. unconjugated) vaccines (e.g. Streptococcus pneumoniae or Salmonella typhi Vi). Antibody responses to naturally encountered antigens e.g. VZV (Varicella Zoster Virus) may also be useful in assessing the functionality of the immune response.


DESCRIPTION PACK VaccZymeTM Tetanus toxoid IgG kit


Range 0.01-7 IU/mL Tetanus toxoid IgG1 kit


Range 0.67-54 mg/L VaccZyme PCP IgG kit


Range 3.3-270 mg/L VaccZyme PCP IgA kit


Range 0-270 U/mL VaccZyme PCP IgM kit


Range 0-270 U/mL PCP IgG2 kit


Range 1.1-90 mg/L VaccZyme Hib IgG kit Range 0.11-9 mg/L


Diphtheria toxoid IgG kit


Range 0.004-3 IU/mL VaccZyme Diphtheria toxoid IgG kit


Alternative to Vero cell assay Range 0.012-3 IU/mL VaccZyme Salmonella typhi Vi IgG kit


Range 7.4-600 U/mL VaccZyme VZVgp


Low Level IgG kit Range 10-810 mIU/mL


PCP = Pneumococcal Capsular Polysaccharide. These kits utilise PneumovaxTM


vaccine. * For research use only More information at: www.bindingsite.com 19


96 test 96 test


96 test 96 test


96 test 96 test 96 test


96 test 96 test


96 test 96 test CODE


MK010 MK011*


MK012 MK120


MK121 MK013* MK016


MK014 MK114


MK091 MK092


Plasma Screening


The accurate measurement of specific antibodies is also important during the manufacturing of therapeutic immunoglobulin and hyperimmune products. Plasma donors are screened for the presence of specific antibodies and donor units with high levels are selected as raw material for the production of therapeutic immunoglobulin products.


The kits below have been designed specifically for this purpose and have higher measuring ranges than the corresponding standard products. The pack size is larger than standard products to allow for economical and consistent testing of high volumes of samples.


A Tetanus toxoid assay for plasma screening is also available on Binding Site’s SPAPLUS Specialist Protein Analyser - see page 9.


DESCRIPTION PACK VaccZyme Tetanus toxoid IgG kit


Range 0.25-60 IU/mL (1:200) Range 1.23-300 IU/mL (1:1000)


Classical Complement Pathway (CH50)


The Classical Complement Pathway CH50 Eq EIA is designed to measure the total complement function of the classical pathway. The measurement of CH50 is recommended as part of the diagnostic protocol for the investigation of Primary Immunodeficiency as well as being important in providing additional information for many other disease states such as Systemic Lupus Erythematosus (SLE) and bacterial infections. If a complement deficiency is suspected due to an abnormal CH50 result further testing is performed for specific components of the complement pathway (see page 22 for details of complement component RID kits).


A CH50 assay is also available on Binding Site’s SPAPLUS Specialist Protein Analyser - see page 8.


DESCRIPTION PACK Classical Complement


Pathway CH50 Eq EIA kit Range 0-250 CH50 Eq U/mL


96 test CODE MK095 10x96 test CODE MK010.4


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28